ClinicalTrials.gg
Not yet recruitingNCT07135245Updated Aug 22, 2025

Improved Treatment and Monitoring of Alzheimer's Disease

A Phase 2 interventional study of Semaglutide (Rybelsus®) combined with other interventions and Placebo in Alzheimer Disease (AD), sponsored by Rune Skovgaard Rasmussen. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Rune Skovgaard Rasmussen · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Sex
All
01

Study summary

In the world's high-income countries, Alzheimer's disease and other dementia diseases are currently the second most common cause of death. This is a recent change, as strokes in the form of blood clots or bleedings in the brain previously were the second most common cause of death.

In Denmark 90,000 live with dementia and life expectancy after dementia diagnosis is 5 to 8 years. Of these, 50,000 have Alzheimer's disease. By 2040 due to a steep increase of the elderly population, the number of people with dementia in Denmark is expected to profoundly increase to 120,000-146,000. This is a concerning forecast which calls for action for several reasons. First and foremost, for the sake of the many thousands of persons who will experience dementia. Every three hours, a Dane dies of dementia. There is currently no cure for Alzheimer's disease and there is a need for the development of an effective therapy. The use of cholinesterase inhibitors, such as donepezil, galantamine and rivastigmine, and the NMDA receptor antagonist memantine, may relieve symptoms, but cannot stop disease progression.

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease. Dementia rate was significantly lower both in type 2 diabetic patients randomized to GLP-1 RAs versus placebo (hazard ratio: 0.47) and in a nationwide Danish registry-based cohort (HR: 0.89) with yearly increased exposure to GLP-1 RAs in a publication on pooled data from three randomized double-blind placebo-controlled trials (15,820 patients) and the cohort (120,054 patients). It is not known whether treatment with GLP-1 RAs may reduce the incidence of dementia in patients without diabetes. There are ongoing studies of whether the GLP-1 RA semaglutide (Rybelsus®), which has a 94% similarity to the naturally occurring human GLP-1 hormone, has a positive effect on early Alzheimer's disease, namely the EVOKE and EVOKE Plus clinical trials.

In this present placebo-controlled clinical trial, the effect of semaglutide (Rybelsus®) on cognitive impairment in Alzheimer's disease will be investigated. The primary hypothesis is that treatment with semaglutide (Rybelsus®) in combination with other treatments will reduce the progression of the cognitive impairment compared to the control group. In comparison with the EVOKE trials focusing on semaglutide as monotherapy, this present trial will investigate the effect of semaglutide both alone and combined with other treatments.

The secondary hypothesis is that patients with mild cognitive impairment and Alzheimer's disease have a more frequent incidence of gingivitis and periodontitis, especially with the bacterium Porphyromonas gingivalis producing its toxins in the oral cavity. Recent research has indicated that this bacteria from the mouth and gingiva through the bloodstream can spread to the brain and be a trigger for Alzheimer's disease. Lactobacillus rhamnosus (LGG) has demonstrated to decrease the level of Porphyromonas gingivalis in plaque along with reduction in gingivitis.

Further hypotheses tested in this trial

  • Administration of candesartan to patients with biomarker-confirmed initial-stage Alzheimer's disease will decrease levels of amyloid markers, improve cognitive function, and enhance brain connectivity.
  • Daily multivitamin-mineral, including vitamin D and calcium supplementation, will improve global cognition, episodic memory, and executive functions in older adults.
  • Alzheimer's disease is associated with certain abnormalities of vision and of the structure of the visual system, both of which can precede the development of symptoms of cognitive decline. Hard drusen are yellow deposits under the retina typically made up of lipids and proteins, which may predict retinal pathology, were more commonly found in the temporal region of Alzheimer's disease retinas compared to retinas of normal older patients. Retinal nerve fiber layer thickness will be measured, retinal drusen, retinal hyper-reflective foci, and foveal avascular zone area in patients with treated Alzheimer's disease compared to controls.
  • Gait analysis will be performed and may be particularly sensitive to early symptoms of dementia development.
    • Biomarkers (p-beta-amyloid, p-tau217 and p-tau181) in cerebrospinal fluid (CSF) will be measured to support suspected Alzheimer's disease.
02

Conditions studied

  • Alzheimer Disease (AD)

Browse trials for

Keywords

  • Alzheimer Disease
  • Semaglutide
  • Cognition
  • Dental care
  • retinal hyper-reflective foci
03

In context

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's planned enrollment of 180 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Rune Skovgaard Rasmussen is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Decreased cognitive abilities corresponding to 16-25 points in the (MMSE)
  • The cognitive impairment must be supported by the presence of specific levels in cerebrospinal fluid (CSF) of β-Amyloid1-42 (≤1030 pg/ml) and Tau (total and phosphorylated, respectively over 300 pg/ml and 27 pg/ml)
  • MRI scan of the brain with coronal sections showing substance loss (atrophy) of the medial part of the temporal lobe compatible with Alzheimer's disease
  • PET scan of the brain (18F-FDG PET) with decreased regional glucose metabolism in the temporal and parietal regions and PiB (PiB-PET scan) with amyloid plaques in the brain compatible with Alzheimer's disease

Exclusion criteria

Exclusion Criteria:

  • Patients with active cancer, and in chemo- or radiation therapy
  • Severe cardiovascular disease.
  • Hepatic insufficiency with ASAT> 2 x or renal insufficiency with serum creatinine > 200 micromol/l
  • Severe epilepsy with frequent tonic-clonic (grand mal) seizures
  • Insulin treatment (type 1 diabetes mellitus) and diabetic ketoacidosis
  • Severe chronic disease (e.g., cirrhosis, AIDS, chronic kidney failure)
  • Severe mental illness e.g., schizophrenia, or physical disabilities leading to inability to participate in intervention or tests, or to provide
  • Evidence for other primary causes of neurodegeneration or dementia, e.g., significant cerebrovascular disease (whose primary cause of dementia was vascular in origin), Lewy Body disease, Parkinson's disease, Fronto-temporal dementia
  • Significant ongoing psychiatric or substance abuse problems.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Intervention - semaglutide only

    An intervention group treated with semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily and placebo.

    Drug: Semaglutide (Rybelsus®)

  • Placebo comparator
    Control

    A control group treated with placebo and no further intervention.

    Other: Placebo

  • Experimental
    Intervention - combination

    An intervention group will be treated with semaglutide (Rybelsus®) 3 mg daily for 4 weeks, followed by 7 mg daily for 4 weeks, and subsequently 14 mg daily. The intervention will also include candesartan up to 32 mg daily, a multivitamin-mineral tablet containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®).

    Drug: Semaglutide (Rybelsus®) combined with other interventions

Interventions

  • DrugSemaglutide (Rybelsus®) combined with other interventions

    Drug page: SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The full intervention includes treatment with semaglutide (Rybelsus®) 3 mg daily for 4 weeks, followed by 7 mg daily for 4 weeks, and subsequently 14 mg daily. The intervention will also include candesartan up to 32 mg daily, a multivitamin-mineral tablet containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®)

    Also known as: Candesartan, multivitamin-mineral tablets containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®), Combination group

  • OtherPlacebo

    A control group treated with placebo and no further intervention

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    An intervention group treated with semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily and placebo

06

What researchers measure

Primary outcomes

  1. The Montreal Cognitive Assessment

    The Montreal Cognitive Assessment is a cognitive screening instrument which provides an estimate of the level of intellectual functioning. Scores are from 0 to 30, where a score of 26 or higher is considered normal. Montreal Cognitive Assessment is moreover sensitive to mild cognitive problems as well as dementia. Studies have shown that Montreal Cognitive Assessment is more sensitive than Mini Mental State Examination to detecting mild cognitive changes and is as effective in identifying the incidence of Alzheimer's disease.

    Time frame: At inclusion, and 52 and 78 weeks.

Secondary outcomes

  1. Measurement of β-Amyloid1-42

    Measurement in CSF of β-Amyloid1-42 using the Elecsys System Cobas® provided by Roche Diagnostics, Denmark, where more pronounced changes in markers for positive identification of Alzheimer's disease in the control group will be expected. Measurements of beta-amyloid, vitamin D and Herpes Simplex Virus (HSV-1) will be carried out by the medical investigator.

    Time frame: Performed at inclusion, and 6, 12, and 18 months.

  2. Measurement of Tau

    Measurement in CSF of Tau (total and phosphorylated) using the Elecsys System Cobas® provided by Roche Diagnostics, Denmark, where more pronounced changes in markers for positive identification of Alzheimer's disease in the control group will be expected. CSF levels of phosphorylated p-tau217 and p-tau181 are measured at inclusion and thereafter every 6 months.

    Time frame: At inclusion, and 6, 12, and 18 months

  3. MRI scan of the brain

    Registration of substance loss (atrophy) of the medial part of the temporal lobe demonstrated in coronal sections, compatible with Alzheimer's disease, will be performed, and patients will be monitored for other kinds of brain pathologies. We will use resting state fMRI data to analyze trends of functional connectivity alterations in the patients.

    Time frame: At inclusion, and 52 and 78 weeks.

  4. PET scan of the brain

    PET scans will be performed using (18F-FDG PET) to identify any decreased regional glucose metabolism in the temporal and parietal regions and PiB (PiB-PET scan) with amyloid plaques in the brain compatible with Alzheimer's disease.

    Time frame: At inclusion, and 52 and 78 weeks.

  5. Clinical Dementia Rating scale - Sum of Boxes

    Clinical Dementia Rating scale - Sum of Boxes (CDR-SB) scores reliably discriminated between mild cognitive impairment (MCI) and very early Alzheimer disease.The CDR-SB provides a more quantitative measure than the single "Global CDR Score." It is considered more sensitive to early cognitive changes and is useful for tracking changes over time, especially in clinical trials. General guidelines for interpreting the CDR-SB score are as follows: 0: Normal 0.5 - 4.0: Questionable cognitive impairment to very mild dementia 4.5 - 9.0: Suggests mild dementia 9.5 - 15.5: Suggests moderate dementia 16.0 - 18.0: Suggests severe dementia

    Time frame: At inclusion, and 52 and 78 weeks.

  6. Symbol Digit Modalities Test

    Danish norms exists. Participants are given a key showing a set of geometric symbols and their corresponding digits (e.g., a "\]" symbol corresponds to the number "4"). They then have a grid of symbols and must quickly write or say the correct digit for each symbol. The test is timed, with a standard duration of 90 seconds. The raw score is simply the total number of correct substitutions made within that 90-second interval. Incorrect or omitted responses do not count. Higher scores are better.

    Time frame: At inclusion, and 52 and 78 weeks

  7. Quality of Life - Alzheimer's Disease (QoL-AD).

    The Quality of Life-Alzheimer's Disease (QoL-AD) scale is a widely used tool for assessing the subjective well-being of individuals with Alzheimer's and other forms of dementia. It is scored in a straightforward manner, but its key feature is that it can be completed by both participants and caregivers (proxy), which allows for a more comprehensive view of their quality of life. The QoL-AD consists of 13 items covering various life domains, such as physical health, energy, mood, living situation, memory, family, friends, and the ability to do things for fun. Each of the 13 items is rated on a 4-point scale: 1. = Poor 2. = Fair 3. = Good 4. = Excellent The total score is the sum of the ratings for all 13 items. The minimum possible score is 13 (1 point for each of the 13 items), and the maximum is 52 (4 points for each item). A higher score indicates a better quality of life.

    Time frame: At inclusion, and 52 and 78 weeks

  8. Patient Global Impression of Change (PGI-C).

    The Patient Global Impression of Change (PGI-C) is a single-item, patient-reported outcome measure used to evaluate a patient's overall perception of how their condition has changed since the start of a treatment or study. Scoring is based on a simple, usually 7-point, Likert scale. The PGI-C is a self-administered questionnaire that asks the patient to rate the change in their condition. The scale ranges from "very much worse" to "very much improved," with "no change" as the midpoint. Instead of a total score like other scales, the PGI-C result is a single number corresponding to the patient's selected response. The interpretation is often dichotomous, meaning it's used to classify patients into "improved" or "not improved." The PGI-C is considered a "gold standard" for assessing a subjective experience of change because it directly asks them what participants think. This is useful in clinical trials to complement objective measures and provide participant-centered perspectives.

    Time frame: At inclusion, and 52 and 78 weeks

  9. European Quality of Life-5 Dimensions Questionnaire (EuroQol-5D™, EQ-5D)

    The EuroQol-5 Dimensions (EQ-5D) is a widely used, standardized instrument for measuring health-related quality of life. It is scored in two main parts, which are often used independently or together: the descriptive system and the EQ Visual Analogue Scale (EQ VAS). The responses to the five dimensions are combined into a 5-digit code or "health profile." For example, a response of "no problems," "slight problems," "moderate problems," "severe problems," and "extreme problems" would be represented by the health profile 12345 on the EQ-5D-5L. A score of 11111 represents perfect health. A descriptive health profile (e.g., 11123), which can be converted into a single index value (utility score) using a country-specific value set. The EQ Visual Analogue Scale (EQ VAS) is a separate, single-item component of the EQ-5D, where participants are asked to rate their overall health "today" on a vertical scale from 0 to 100. The score is simply the number the respondent marks on the scale..

    Time frame: At inclusion, and 52 and 78 weeks

  10. The Major Depression Inventory (MDI)

    The Major Depression Inventory (MDI) is a self-report questionnaire used to assess depressive symptoms and the severity of depression. As a severity scale, MDI provides a total score that indicates the degree of depressive symptoms. Total Score: The scores from all 10 items are summed up. The theoretical range of the total score is from 0 (no depression) to 50 (maximum depression).

    Time frame: At inclusion, and 52 and 78 weeks.

  11. The Rey-Osterrieth Complex Figure Test

    The Rey-Osterrieth Complex Figure (ROCF) test is a neuropsychological assessment used to evaluate visuospatial abilities, memory, and executive functions. Participants copy an advanced visual figure (without later recall). Rey-Osterrieth Complex Figure is scored by a trained clinician who systematically evaluates the accuracy and placement of 18 specific components, with a maximum possible score of 36, higher scores are best. This process provides a quantitative measure of visuospatial and memory skills and a qualitative understanding of the individual's cognitive strategy. Danish norms exist. The test is sensitive to Alzheimer's disease.

    Time frame: At inclusion, and 52 and 78 weeks.

  12. The 12-item Neuropsychiatric Inventory (NPI-12)

    The 12-item Neuropsychiatric Inventory (NPI-12) is scored based on a structured interview with a caregiver who knows the patient well. Only the Caregiver Distress Scale will be used. For each of 12 symptom domain where a behavior is present, the caregiver is asked to rate how distressing the behavior is for them personally. Distress Rating: This is rated on a scale from 0 to 5: 0: Not distressing at all 1. Minimal 2. Mild 3. Moderate 4. Severe 5. Extreme or very severe The Total Caregiver Distress Score range from 0 (best) to 60 (worst). This score helps researchers understand the impact of the patient's behaviors on their caregivers.

    Time frame: At inclusion, and 52 and 78 weeks.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Sep 2030, 56 months later.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 56 months is close to that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 22, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Sep 30, 2030
CompletionEst.
Sep 30, 2031
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07135245
Lead sponsor
Rune Skovgaard Rasmussen
Collaborators
Herlev Hospital
Responsible party
Rune Skovgaard Rasmussen (MSc, PhD, associate professor of General Pathology, University Hospital, Gentofte, Copenhagen) — Sponsor-investigator
First posted
Aug 22, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Sep 30, 2030 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Aug 22, 2025

Study contacts

Karsten OVergaard, MD, Specialist in Neurology
Contact
karsten.overgaard@regionh.dk
+4526172611
Rune S Rasmussen, MSc (neuropsychology), PhD
Contact
rsr@sund.ku.dk
+4528757500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion